drugset
drugset / Trial / NCT02959892

A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)

NCT02959892 ↗

Phase 1 Completed 12 enrolled Neurocrine Biosciences Takeda · collab
Non-randomizedSingle-groupOpen-labelOther

Summary

The purpose of this study is to determine brain penetration of single oral doses of TAK-041 and its effects on amphetamine-induced dopamine release in the Central Nervous System (CNS).

Timeline

Start
2016-12-05
Primary completion
2017-05-30
Completion
2017-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject ZELATRIAZIN Small molecule 20 mg Oral
Subject ZELATRIAZIN Small molecule 40 mg Oral
Background Amphetamine Unknown 0.25 mg/kg Oral
Background Amphetamine Unknown 0.5 mg/kg Oral
Background [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) Unknown 180 mbq Intravenous

Indications

No indication recorded.